Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Nuclear Medicine|March 7, 2017
The Wandering Mesenteric Lymph Node: Delayed 68Ga-DOTANOC PET/CT Imaging to Overcome a Potential PitfallLucia Zanoni, Maurizio Zompatori, Federica Scalorbi, et al.
Biomedicines|October 27, 2022
Conventional MRI-Derived Biomarkers of Adult-Type Diffuse Glioma Molecular Subtypes: A Comprehensive ReviewPaola Feraco, Rossana Franciosi, Lorena Picori, et al.
Annals of Nuclear Medicine|May 26, 2018
Correction to: Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroidFederico Caobelli, Agostino Chiaravalloti, Laura Evangelista, et al.
Annals of Nuclear Medicine|October 8, 2017
Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroidFederico Caobelli, Agostino Chiaravalloti, Laura Evangelista, et al.
Breast Cancer (Dove Medical Press)|July 26, 2017
Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrenceRoberta Piva, Flavia Ticconi, Valentina Ceriani, et al.
Scientific Reports|July 9, 2024
Cylindrical TGR as early radiological predictor of RLT progression in GEPNETs: a proof of conceptFederica Scalorbi, Enrico Matteo Garanzini, Giuseppina Calareso, et al.
Tumori|August 18, 2021
Update on radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effectsValentina Fuoco, Giovanni Argiroffi, Stefania Mazzaglia, et al.
Scientific Reports|October 1, 2021
Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRTFederica Scalorbi, Giovanni Argiroffi, Michela Baccini, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 5, 2024
The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATEMarco Maccauro, Mariarosaria Cuomo, Matteo Bauckneht, et al.
Journal of Endocrinological Investigation|October 12, 2024
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM)Francesco Panzuto, Manuela Albertelli, Maria Luisa De Rimini, et al.
Pageof 2